Spruce Street Capital Lp
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$415.9M
Q ending 2026-03-31
Prior quarter
$302.7M
Q ending 2025-12-31
Change
+37.4% QoQ
Positions
28
reported holdings
Largest positions
All 28 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Relmada Therapeutics Inc | RLMD | Shares | $43.0M | 6.3M |
| Kiniksa Pharmaceuticals I | Shares | $36.6M | 761K | |
| Lb Pharmaceuticals Inc | LBRX | Shares | $33.6M | 1.4M |
| Dianthus Therapeutics In | DNTH | Shares | $31.3M | 373K |
| Relay Therapeutics Inc | RLAY | Shares | $29.7M | 3.0M |
| Alto Neuroscience Inc | ANRO | Shares | $29.1M | 1.3M |
| Centessa Pharmaceuticals | 260 | Shares | $19.5M | 490K |
| Savara Inc | SVRA | Shares | $18.5M | 3.4M |
| Kalvista Pharmaceuticals | 4XC1 | Shares | $18.1M | 898K |
| Vaxcyte Inc | PCVX | Shares | $14.3M | 246K |
| Enliven Therapeutics Inc | ELVN | Shares | $12.9M | 329K |
| Surrozen Inc Com New | SRZN | Shares | $12.6M | 432K |
| Enanta Pharmaceuticals I | ENTA | Shares | $11.8M | 933K |
| Alkermes Plc | Shares | $11.2M | 318K | |
| Perspective Therapeutics | CATX | Shares | $11.0M | 2.6M |
| Minerva Neuroscienc | NERV | Shares | $10.0M | 1.7M |
| Century Therapeutics | IPSC | Shares | $9.2M | 4.1M |
| Alumis Inc | ALMS | Shares | $8.6M | 393K |
| Sab Biotherapeutics In | SABS | Shares | $8.4M | 2.2M |
| Erasca Inc | ERAS | Shares | $6.8M | 423K |
| Inhibikase Therapeuti | IKT | Shares | $6.0M | 3.6M |
| Maze Therapeutics Inc | MAZE | Shares | $6.0M | 200K |
| An2 Therapeutics Inc | ANTX | Shares | $5.6M | 1.7M |
| Lexeo Therapeutics Inc | LXEO | Shares | $5.3M | 929K |
| Helix Acquisition Corp Iii | Shares | $5.1M | 500K | |
| Alector Inc | ALEC | Shares | $4.5M | 2.1M |
| Leonabio Inc | LONA | Shares | $3.8M | 394K |
| Corvus Pharmaceuticals I | CRVS | Shares | $3.4M | 232K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.